Results 111 to 120 of about 213,451 (221)

FORMULATION AND EVALUATION OF DULOXETINE HYDROCHLORIDE TRANSDERMAL PATCHES

Transdermal patches are a non-invasive method of drug administration. It is an adhesive patch designed to deliver a specific dose of medication through the skin and into the blood stream throughout the body. Transdermal drug delivery system is an advanced drug administration technique.
openaire   +2 more sources

Transaminitis from Duloxetine: Case Report

Introduction: Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is commonly prescribed for depression, anxiety, and neuropathic pain. Although rare, duloxetine has been associated with hepatotoxicity.
Gayle Galletta, Savant Mehta, Daniel Jancura, Irene Li, Daminica Ryan   +4 more
core   +1 more source

Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials

Journal of Pain Research, 2017
Levent Alev,1 Shinji Fujikoshi,2 Aki Yoshikawa,3 Hiroyuki Enomoto,1 Mitsuhiro Ishida,4 Toshinaga Tsuji,5 Kei Ogawa,1 Shinichi Konno6 1Bio-Medicine, 2Statistical Science, 3Scientific Communications, Medicines Development Unit, Eli Lilly Japan K.K., Kobe ...
Alev L, Fujikoshi S, Yoshikawa A, Enomoto H, Ishida M, Tsuji T, Ogawa K, Konno S   +7 more
doaj  

The role of duloxetine in the treatment of anxiety disorders

, 2008
Domenico De Berardis1,2,3, Nicola Serroni2, Alessandro Carano1,4, Marco Scali1,4, Alessandro Valchera5, Daniela Campanella1,2, Alessandro D’Albenzio1, Berardo Di Giuseppe2, Francesco Saverio Moschetta2, Rosa Maria Salerno1, Filippo Maria ...
Marco Scali, Nicola Serroni, Domenico De Berardis, Alessandro Carano, Alessandro Valchera, et al   +5 more
core  

Review of duloxetine in the management of diabetic peripheral neuropathic pain

, 2008
Timothy Smith1, Robert A Nicholson21Mercy Health Research Ryan Headache Center, St. Louis, MO, USA; 2Department of Family Medicine, Saint Louis University School of Medicine, St.
Timothy Smith, Robert A Nicholson
core  

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan

, 2015
Eiji Harada,1 Alexander Schacht,2 Tsukasa Koyama,3 Lauren Marangell,4,5 Toshinaga Tsuji,6 Rodrigo Escobar41Medical Science, Eli Lilly Japan K.K, Kobe, Japan; 2Global Statistical Sciences, Eli Lilly and Company, Bad Homburg, Germany; 3Clinical Research ...
Schacht A, Tsuji T, Koyama T, Marangell LB, Harada E, Escobar R   +5 more
core  

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis

, 2017
Atsushi Kuga,1 Toshinaga Tsuji,2 Shinji Hayashi,2 Mako Matsubara,3 Shinji Fujikoshi,4 Hirofumi Tokuoka,1 Aki Yoshikawa,5 Rodrigo Escobar,6 Kazuhide Tanaka,7 Takaharu Azekawa8 1Bio Medicine, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe ...
Fujikoshi S, Tsuji T, Escobar R, Hayashi S, Kuga A, Azekawa T, Matsubara M, Yoshikawa A, Tanaka K, Tokuoka H   +9 more
core  

Extended-Release Formulation of Duloxetine Hydrochloride: A Comprehensive Review

AbstractExtended-release drug delivery systems are designed to maintain a consistent therapeutic drugconcentration in the bloodstream over an extended period. Duloxetine Hydrochloride is a SelectiveSerotonin and Norepinephrine Reuptake Inhibitor (SNRI) widely used in the treatment of majordepressive disorder, generalized anxiety disorder, diabetic ...
openaire   +2 more sources

Use of select medications prior to duloxetine initiation among commercially-insured patients

, 2012
Mark Bernauer,1 Ning Wu,2 Shih-Yin Chen,2 Xiaomei Peng,1 Luke Boulanger,2 Yang Zhao11Eli Lilly and Company, Indianapolis, IN, 2United BioSource Corporation, Lexington, MA, USABackground: The purpose of this study was to assess select medication ...
Peng X, Chen SY, Bernauer M, Wu N, Zhao Y, Boulanger L   +5 more
core